Monograph Details
|
|
Endocrine System
> Diabetes
|
|
HUMULIN 70/30 |
| Manufacturer |
|
Lilly, Eli and Company |
| Legal Classification |
|
OTC |
| Generic Name |
|
Insulin isophane suspension (NPH) 70% (human, recombinant), regular insulin 30% (human, recombinant) 100Units/mL; inj. |
| Also |
• HUMULIN 50/50
• HUMULIN N
• HUMULIN R
|
| Indications |
|
Diabetes. |
| Adults and Children |
|
SC injection only. Onset approx 30 minutes, peak 2–12 hrs, duration up to 24 hrs. |
| Precautions |
|
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. |
| Interactions |
|
Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol. Onset may be delayed if regular insulin is mixed with zinc insulin. Regular and NPH insulins may be mixed and used immediately or stored for future use. |
| Adverse Reactions |
|
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema. |
| How Supplied |
All—10mL vials
Prefilled disposable Pen (70/30, N)—5x3mL |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
